Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus

Recombinant human deoxyribonuclease (rhDNase) has been demonstrated to reduce the viscosity of purulent cystic fibrosis (CF) respiratory mucus, to improve pulmonary function and to reduce the risk of respiratory tract infectious exacerbations, but its effect on mucus transportability has not so far been investigated. The dose-dependent effect of rhDNase was analysed in vitro on mucus transport rate (tr) by ciliary activity and by simulated cough (cough transport (ct)), as well as on mucus viscosity and surface properties. Purulent CF sputa (n = 15) were incubated for 30 min at 37 degrees C with either rhDNase at three different concentrations (final concentrations 0.2, 2 or 20 micrograms.ml-1 of mucus) or placebo. No significant dose-dependent effect of rhDNase on the mucociliary transport rate was observed when the samples wer statistically analysed together. However, in the larger group of mucus samples (n = 11) with a low initial mucociliary transport rate, the latter was improved at each rhDNase concentration (tr0.2 = 0.69, tr2 = 0.88 and tr20 = 0.87) as compared to placebo (trp = 0.58). In the smaller group of mucus samples (n = 4) with high initial transport rate, a decrease in mucociliary transport rate was observed, particularly at the highest concentration rhDNase assayed, i.e. 20 micrograms.ml-1 of mucus (tr20 = 0.58) as compared to placebo (trp = 0.86). The mucus cough transport was increased by rhDNase (ct0.2 = 25 mm, ct2 = 27.5 mm and ct20 = 31 mm) as compared to placebo (ctp = 23.5 mm).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				N N Sanders, H Franckx, K De Boeck, J Haustraete, S C De Smedt, and J Demeester Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax, November 1, 2006; 61(11): 962 - 966. [Abstract] [Full Text] [PDF]

				F Ratjen, C-M Hartog, K Paul, J Wermelt, and J Braun Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha Thorax, November 1, 2002; 57(11): 930 - 934. [Abstract] [Full Text] [PDF]

				N. N. SANDERS, E. VAN ROMPAEY, S. C. DE SMEDT, and J. DEMEESTER Structural Alterations of Gene Complexes by Cystic Fibrosis Sputum Am. J. Respir. Crit. Care Med., August 1, 2001; 164(3): 486 - 493. [Abstract] [Full Text] [PDF]

				J.-M. ZAHM, C. DEBORDEAUX, C. MAURER, D. HUBERT, D. DUSSER, N. BONNET, R. A. LAZARUS, and E. PUCHELLE Improved Activity of an Actin-resistant DNase I Variant on the Cystic Fibrosis Airway Secretions Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1153 - 1157. [Abstract] [Full Text]

				S. Baconnais, R. Tirouvanziam, J.-M. Zahm, S. de Bentzmann, B. Péault, G. Balossier, and E. Puchelle Ion Composition and Rheology of Airway Liquid from Cystic Fibrosis Fetal Tracheal Xenografts Am. J. Respir. Cell Mol. Biol., April 1, 1999; 20(4): 605 - 611. [Abstract] [Full Text]

				J.-M. ZAHM, C. GALABERT, A. CHAFFIN, J.-P. CHAZALETTE, C. GROSSKOPF, and E. PUCHELLE Improvement of Cystic Fibrosis Airway Mucus Transportability by Recombinant Human DNase Is Related to Changes in Phospholipid Profile Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1779 - 1784. [Abstract] [Full Text] [PDF]

				W. FENG, H. GARRETT, D. P. SPEERT, and M. KING Improved Clearability of Cystic Fibrosis Sputum with Dextran Treatment in vitro Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 710 - 714. [Abstract] [Full Text] [PDF]

				M. KING, B. DASGUPTA, R. P. TOMKIEWICZ, and N. E. BROWN Rheology of Cystic Fibrosis Sputum after in vitro Treatment with Hypertonic Saline Alone and in Combination with Recombinant Human Deoxyribonuclease I Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 173 - 177. [Abstract] [Full Text]